EAM Investors’s Tarsus Pharmaceuticals TARS Stock Holding History

EAM Investors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-72,922	Closed	-$5.97M	–	370
2025 Q4	$5.97M	Buy	+72,922	New	+$5.44M	0.67%	35
2025 Q2	–	Sell	-52,413	Closed	-$2.69M	–	345
2025 Q1	$2.69M	Sell	52,413 -19,402	-27%	-$959K	0.47%	109
2024 Q4	$3.98M	Buy	+71,815	New	+$3.26M	0.56%	83
2024 Q2	–	Sell	-100,658	Closed	-$3.66M	–	345
2024 Q1	$3.66M	Buy	+100,658	New	+$2.96M	0.57%	92

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EAM Investors's TARS Position: Q1 2026 in Review

EAM Investors sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 72,922 shares — an estimated $5.97M sold.

EAM Investors first reported a position in TARS in Q1 2024 and held it in 4 quarters. The position peaked at $5.97M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

EAM Investors reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 72,922 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $5.97M.
EAM Investors first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
EAM Investors's Tarsus Pharmaceuticals position peaked at $5.97M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.